HomeAI · summaries
Storia in 7 fonti
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed after an advisory committee voted against the breast cancer prospect.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
FDA delays decision on AstraZeneca breast cancer pill
The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive in what would be a new kind of treatment setting.
- ·
independent.co.uk
AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data
This extension follows an April vote by a majority of the FDA's advisory panel against the drug when used in combination with a CDK4/6 inhibitor
- ·
AstraZeneca breast cancer pill faces review delay from regulators
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…
- ·
fiercebiotech.com
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses…
- ·
fiercepharma.com
Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin (bevacizumab) in the U.S., with the FDA now agreeing that the…
- ·
statnews.com
Pharmalittle: We're reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
The FDA extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel voted against the drug
- ·
endpoints.news
AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
Kailera touts early weight loss data; Arrowhead takes a shot at the same obesity target as Wave; FDA delays AstraZeneca’s camizestrant PDUFA date; and more
- ·
pharmaceutical-technology.com
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory limbo.
- ·
AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday